Navigation Links
Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
Date:10/13/2008

red to TAXUS (4.1 percent for XIENCE V vs. 6.8 percent for TAXUS, p-value=0.03)*.

-- Low rates of stent thrombosis between one and two years, defined as very late stent thrombosis, per Academic Research Consortium (ARC) definition of definite/probable stent thrombosis (0.5 percent for XIENCE V and 0.8 percent for TAXUS). The ARC definitions of stent thrombosis were developed to eliminate variability in the definitions across various drug eluting stent trials.

* Event rates are based on Kaplan-Meier estimates; p-values are for descriptive purposes only.

Strong Results in Complex Patients: SPIRIT III Subgroup Analyses

Also presented during TCT, a variety of subgroup analyses from the SPIRIT III trial demonstrated observational evidence of strong performance by XIENCE V in a variety of patients and lesion types that represent complex patients. The results consistently favored XIENCE V compared to TAXUS at two years across multiple subgroups examined, including patients with small vessels and multi-vessel patients. In diabetic patients, the analysis showed there were no observed differences between XIENCE V and TAXUS at two years. The SPIRIT III trial was not designed to analyze statistical differences in any of the patient subgroups, as the sample sizes were too small to draw firm conclusions.

"With the subgroup analysis, we saw encouraging trends of lower event rates between one and two years for patients treated with XIENCE V compared to patients treated with TAXUS, regardless of patient or lesion complexity," said John M. Capek, Ph.D., executive vice president, Medical Devices, Abbott. "Even though the SPIRIT III trial was not designed for statistical comparisons in subgroups, these positive trends demonstrate that XIENCE V performs in a consistent manner and gives physicians confidence in XIENCE V as they consider what is the most effective treatment for their patients."

About XIENCE V

XIENCE V is used to treat coron
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
3. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
4. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
5. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
6. Dynavaxs HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
7. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
8. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
9. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
10. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
11. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... MINNEAPOLIS and ORLANDO, Fla. ... data supporting Inspire therapy continues to grow, with the ... paper published on-line in Otolaryngology – Head ... therapy causes a worsening of both objective and subjective ... to directly attribute Inspire therapy for the reduction in ...
(Date:9/19/2014)... -- Over 200 runners participated in the fifth annual 5K ... Institute (ROI), hosted by Radiation Business Solutions. This year the ... Francisco.  "Donations are still coming in," ... Solutions, "but at this point, through registrations and ... ROI this year. This surpasses last year,s record of ...
(Date:9/19/2014)... ANGELES , Sept. 19, 2014  CytRx Corporation ... development company specializing in oncology, today announced that ... present at BioCentury,s 2014 NewsMakers in the Biotech Industry ... Eastern Time. The conference will take place at the ... . A live and archived webcast ...
Breaking Medicine Technology:New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3
... 11, 2012  A study conducted at Scripps Health has ... emergency room patients avoid unnecessary follow-up care.  Scripps Health ... the study titled, "Prevalence of Arrhythmias in Emergency Department ... at the Heart Rhythm Society,s 33rd Annual ...
... cholesterol or high blood pressure are at particular risk ... on taking their medications, according to new research from ... presented this week.  (Logo: http://photos.prnewswire.com/prnh/20080827/EXPRESSSCRIPTSLOGO ... that patients 65 and older who did not take ...
Cached Medicine Technology:Scripps Doctors Study Novel New Device to Diagnose Irregular Heart Beat 2Scripps Doctors Study Novel New Device to Diagnose Irregular Heart Beat 3Scripps Doctors Study Novel New Device to Diagnose Irregular Heart Beat 4Scripps Doctors Study Novel New Device to Diagnose Irregular Heart Beat 5Failure to Take Medicine Linked to Unnecessary Hospital Visits, Especially for Medicare Patients Taking High Blood Pressure or High Cholesterol Medications 2Failure to Take Medicine Linked to Unnecessary Hospital Visits, Especially for Medicare Patients Taking High Blood Pressure or High Cholesterol Medications 3Failure to Take Medicine Linked to Unnecessary Hospital Visits, Especially for Medicare Patients Taking High Blood Pressure or High Cholesterol Medications 4Failure to Take Medicine Linked to Unnecessary Hospital Visits, Especially for Medicare Patients Taking High Blood Pressure or High Cholesterol Medications 5
(Date:9/20/2014)... The festival season is coming soon. The high-end fashion designer ... cocktail dresses . A lot of sophisticated women like its ... new promotion for its high quality clothes. Now, each of ... 20 to 71 percent off. , The company’s cocktail ... provided in many fashionable colors. Mary, the company’s sales manager, ...
(Date:9/20/2014)... September 20, 2014 Recently, Best ... site, has launched its new website. The new ... of popular hosting products for customers. Here, people ... make a purchasing decision. Also, it has recommended ... , One of the great web hosting ...
(Date:9/20/2014)... September 20, 2014 Plumbing construction ... out of 5, indicating a moderately favorable purchasing environment ... score reflects current and future pricing trends that will ... prices. Other factors that negatively affect buyer power are ... construction and the moderate switching costs. Buyers benefit, however, ...
(Date:9/20/2014)... 20, 2014 The Arizona Advanced ... is celebrating National Manufacturing Day by opening its doors ... processing and additive manufacturing labs will be offered between ... at MCC’s Southern and Dobson campus (1833 W. Southern ... Lot D. , The AzAMI at MCC was established ...
(Date:9/19/2014)... (PRWEB) September 20, 2014 Nearly 780 ... of Common Pleas where a meeting took place to ... complaints pending in the court’s mass tort program. ... meet this past week at the Complex Litigation Center ... consolidated for pretrial proceedings. The Risperdal lawsuits filed against ...
Breaking Medicine News(10 mins):Health News:High-end Fashion Designer BellasDress Offers Luxurious Cocktail Dresses For Sophisticated Women 2Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 3Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 4Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4
... the future may be painless and noninvasive, thanks to smart ... test for skin cancer, patients today must endure doctors cutting ... lab and anxiously awaiting the results. Using laser microscopes that ... have the tools to painlessly scan a patient,s troublesome mole ...
... have discovered a signaling pathway that is crucial to ... data, obtained from cells, animals and ALI patients, suggest ... the targets significantly reduced flooding of the lungs that ... is a devastating disease, with 40 percent mortality and ...
... Researchers at Memorial Sloan-Kettering Cancer Center,s Nanotechnology ... Hybrid Silica Technologies, have received approval for their ... US Food and Drug Administration (FDA) for an ... imaging of cancer, which may be useful for ...
... a patient,s immune system and enables them to fight the ... first time in the UK. The treatment will use ... of Southampton, which will treat a selected group of volunteers ... forms of bone marrow and blood cancer. Scientists ...
... MONDAY, Jan. 31 (HealthDay News) -- A man is much more ... another woman than a girlfriend who had sex with another man, ... to stick with a man who had sex with another woman ... The findings provide new insight into the general male desire to ...
... Sprint Fidelis implantable cardioverter-defibrillator (ICD) leads (Medtronic) failed more ... heart disease, according to a multicenter study published online ... that lead failure was not associated with death or ... the patients whose leads fractured experienced painful inappropriate shocks, ...
Cached Medicine News:Health News:Smart lasers could make cancer biopsies painless, help speed new drugs to market 2Health News:Researchers discover signaling pathway crucial to acute lung injury 2Health News:Cancer-targeting investigational nanoparticle receives FDA IND approval for first-in-human trial 2Health News:Cancer-targeting investigational nanoparticle receives FDA IND approval for first-in-human trial 3Health News:Southampton scientists begin patient trials of new leukemia cancer vaccine 2Health News:Southampton scientists begin patient trials of new leukemia cancer vaccine 3Health News:Recalled ICD leads fail in women, youths most often 2
... with obstructive sleep apnea necessitating tracheotomy, or ... Also indicated where airway access for pulmonary ... ,Another excellent choice for a sleep apnea ... series. Available with a low profile inner ...
... additional patient safety, the laryngectomy ... integral 15 mm ISO termination ... a ventilator, with or without ... , ,Portex® laryngectomy tubes ...
... nature of the silicone tube material allows ... and more comfort than tubes made of ... comfortable and compliant neck flange allows the ... irritation. A comprehensive range of sizes insures ...
... that in excess of 10% of all ... a specialized tracheostomy tube. Bivona® Fixed-Flange Hyperflex™ ... and can adapt to the unique anatomical ... extra horizontal length, extra vertical length, ...
Medicine Products: